Is IRTC a Buy? What to Consider in 2026
Short answer
The bull case for IRTC (IRTC) rests on Zio volume growth and category leadership: The core Zio service continues to take share from legacy Holter monitors, which have fallen from about 80% of the market to roughly 40% as long-term continuous monitoring becomes standard of care. Revenue (TTM) is ~$790M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Whether IRTC is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
iRhythm Technologies makes the Zio service, a small adhesive patch that records a patient's heart rhythm continuously for up to 14 days and pairs it with AI-assisted analysis to detect arrhythmias such as atrial fibrillation. The device replaced the older Holter-monitor workflow (short-window, wired recorders) with a longer, more comfortable, water-resistant patch that is mailed back for algorithmic analysis and a physician report. Zio has become the most widely prescribed ambulatory ECG monitor in the US, and iRhythm is extending the franchise with a next-generation mobile cardiac telemetry platform (Zio MCT), international expansion, and adjacencies such as sleep apnea and primary-care risk stratification. The investment picture is a classic high-growth medtech profile. Revenue is compounding in the mid-20s percent, gross margins sit around 70%, and payer coverage now reaches roughly 93% of US lives, but the company is only recently adjusted-EBITDA positive and still posts GAAP net losses. The stock trades at a premium revenue multiple (roughly $4 billion market cap on under $1 billion of trailing revenue), so the valuation embeds continued volume growth, margin expansion, and successful new-product launches. That combination makes IRTC sensitive to reimbursement rate changes, FDA outcomes, and any slowdown in prescription volumes.
What's the case for buying IRTC?
1. Zio volume growth and category leadership
The core Zio service continues to take share from legacy Holter monitors, which have fallen from about 80% of the market to roughly 40% as long-term continuous monitoring becomes standard of care. Q1 2026 revenue rose about 26% year over year to roughly $199 million, driven by sustained volume demand across the customer base. As the most widely prescribed ambulatory ECG monitor in the US, iRhythm benefits from installed physician habit and a large recurring stream of new patient prescriptions.
2. Next-generation Zio MCT and AI
iRhythm has submitted its next-generation Zio MCT (mobile cardiac telemetry) platform to the FDA and reaffirmed a first-half 2027 launch target for the AI-enabled version. MCT is a higher-acuity, real-time monitoring category that expands the addressable market beyond the mail-back patch. Deeper AI in the analysis pipeline is also positioned as a driver of both accuracy and margin over time.
3. Margin expansion toward profitability
Gross margin sits near 71% and the company turned adjusted-EBITDA positive, guiding to a full-year 2026 adjusted-EBITDA margin of roughly 12% to 13%. Operating leverage on a largely fixed analysis and sales infrastructure means incremental volume can flow through at high margins. The narrative has shifted from pure top-line growth toward a structural path to sustained profitability.
4. New markets and payer coverage
Growth catalysts include international expansion, deeper penetration in primary care and population health through risk-stratification partnerships, and adjacencies such as obstructive sleep apnea. US payer coverage now reaches about 93% of lives, reducing reimbursement friction for prescribers. These channels give iRhythm several independent levers to extend growth beyond its core cardiology base.
What are the risks to IRTC?
Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Reimbursement is the other central risk, since a large share of revenue depends on CMS and commercial payer rates that can be cut or restructured. The company still reports GAAP net losses and trades at a premium revenue multiple, so any volume slowdown, pricing pressure, or launch delay could compress the stock sharply. Competition from larger, better-capitalized players (Philips, Boston Scientific) and the possibility of equity issuance under a shelf registration add further risk. Investors should size positions with the understanding that medtech reimbursement and regulatory outcomes are difficult to predict.
How is IRTC valued? (as of JULY 2026)
Snapshot for IRTC as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$790M
- Q1 2026 revenue growth: ~26% YoY
- Gross margin: ~71%
- FY2026 revenue guidance: ~$875M-$885M
- Market cap: ~$4.2B
- Cash and investments: ~$550M
IRTC trades at a premium price-to-sales multiple (roughly $4 billion of market value on under $1 billion of trailing revenue), typical of a high-growth medtech that is still scaling toward consistent GAAP profitability. The company is adjusted-EBITDA positive and guides to a 12% to 13% adjusted-EBITDA margin for 2026, but it still posts GAAP net losses. The valuation therefore leans heavily on continued volume growth and margin expansion rather than current earnings.
How do you decide if IRTC is a buy?
Rather than asking whether IRTC is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold IRTC indirectly through an index or sector ETF before adding more.
For the full picture, see the IRTC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about IRTC against your real portfolio and see your actual exposure before deciding.
The bottom line on IRTC
The bottom line: IRTC's story right now is Zio volume growth and category leadership, with revenue (ttm) at ~$790M. If you believe that narrative continues, the call is about sizing IRTC sensibly and checking overlap with what you own; if you doubt it (the risk: regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around IRTC with Walnut
Use IRTC as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is IRTC a good stock to buy right now?
+
The case for IRTC right now is Zio volume growth and category leadership, with revenue (ttm) at ~$790M. If you believe that thesis holds, IRTC is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does IRTC do?
+
iRhythm Technologies makes the Zio service, a small adhesive patch that records a patient's heart rhythm continuously for up to 14 days and pairs it with AI-assisted analysis to de
What are the main risks of IRTC?
+
Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Reimbursement is the other central risk, since a large share of revenue depends on CMS and commercial payer rates that can be cut or restructured. The company still reports GAAP net losses and trades at a premium revenue multiple, so any volume slowdown, pricing pressure, or launch delay could compress the stock sharply. Competition from larger, better-capitalized players (Philips, Boston Scientific) and the possibility of equity issuance under a shelf registration add further risk. Investors should size positions with the understanding that medtech reimbursement and regulatory outcomes are difficult to predict.
What does iRhythm Technologies (IRTC) do?
+
iRhythm makes the Zio service, an adhesive patch that continuously records a patient's heart rhythm for up to 14 days. The patch is mailed back and analyzed with AI-assisted algorithms to detect arrhythmias like atrial fibrillation, then a report is sent to the prescribing physician.
Is IRTC profitable?
+
iRhythm is adjusted-EBITDA positive and guides to a roughly 12% to 13% adjusted-EBITDA margin for 2026, but it still reports GAAP net losses. Q1 2026 showed a smaller net loss than the prior year alongside about 26% revenue growth, so profitability is improving but not yet consistent on a GAAP basis.
How fast is iRhythm growing?
+
Revenue grew about 26% year over year in Q1 2026 to roughly $199 million, and the company raised full-year 2026 guidance to about $875 million to $885 million, implying roughly 17% to 18% annual growth. Growth is driven by rising Zio prescription volumes and expanding payer coverage.
What is the Zio MCT and why does it matter?
+
Zio MCT is iRhythm's next-generation mobile cardiac telemetry platform, submitted to the FDA with an AI-enabled version targeted for a first-half 2027 launch. It expands iRhythm into real-time, higher-acuity monitoring, a larger addressable market beyond the mail-back patch.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell IRTC; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.